Science Sub-Journal: Combined use of low-dose radiotherapy and immunotherapy can eradicate metastatic cancer in mice

July 21, 2021 News//---More does not necessarily mean better, such as in cancer treatment

In a new study, researchers from the University of Pittsburgh School of Medicine and the University of Wisconsin-Madison found that the combination of targeted radionuclide therapy and immunotherapy can significantly increase the risk of metastatic cancer in mice.

Clinical trial tumor

Immunotherapy has completely triggered a revolution in cancer treatment by helping the patient's immune system fight cancer

Tumor

In these cases, oncologists have discovered that external beam radiotherapy (EBRT) --- placing patients in a carefully calibrated machine and directing a beam of radiation directly at their tumor --- can help "Cold" or resistant tumors turn into "hot" tumors , making immunotherapy more effective

Oncologists have discovered that external beam radiotherapy (EBRT) - placing patients in a carefully calibrated machine and directing a beam of radiation directly at their tumor - can help to treat the "cold" or It is said that resistance-resistant tumors become "hot" tumors , which makes the therapeutic effect of immunotherapy better

Tumor

Tumor

Morris said, “ In view of the fact that radiation from targeted radionuclide therapy is delivered at too high a dose or at the wrong time, it may kill or harm tumor-infiltrating immune cells, and we ultimately want these immune cells to destroy tumors.

In view of the fact that radiation from targeted radionuclide therapy at too high a dose or delivered at the wrong time, it may kill or damage tumor infiltrating immune cells, and we ultimately want these immune cells to destroy tumors, so we are designing this type of During the research, it is very important to accurately determine the radiation dose and the delivery time of this radiation dose in the tumor

Tumor

To their surprise, the dose of radiotherapy given to mice alone was too low to kill the cancer, but when low-dose radiotherapy was given to the mice together with immunotherapy, their cancer was cured

To their surprise, the dose of radiotherapy given to mice alone was too low to kill the cancer, but when low-dose radiotherapy was given to the mice together with immunotherapy, their cancer was cured

Patel said that low-dose radiotherapy is not destroying the tumor, but "stressing the cells in the tumor," which stimulates the immune system's usual response to infection

Patel said, “In order to develop our findings into a new standard of treatment, human clinical trials are needed

Clinical Trials

Reference:

References:

Ravi B.
Patel et al.
Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade .
Science Translational Medicine, 2021, doi:10.
1126/scitranslmed.
abb3631.
Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade